2269.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:08):

Stats
今日成交量	43.91M
平均成交量	57.74M
市值	59.46B
EPS	HKD0 ( 2024-03-26 )
下一个收益日期	( HKD0 ) 2024-06-19
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	16.82
ATR14	HKD0.0200 (0.14%)

音量相关性

長: 0.30 (neutral)

短: 0.94 (very strong)

Signal:(54.021) Expect same movement, but be aware

WuXi Biologics (Cayman) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

WuXi Biologics (Cayman) 相关性 - 货币/商品

-0.77
( moderate negative )

-0.70
( moderate negative )

0.00
( neutral )

-0.86
( strong negative )

-0.34
( neutral )

-0.15
( neutral )

WuXi Biologics (Cayman) 财务报表

Annual	2023
营收:	HKD17.03B
毛利润:	HKD6.83B (40.08 %)
EPS:	HKD0.770

FY	2023
营收:	HKD17.03B
毛利润:	HKD6.83B (40.08 %)
EPS:	HKD0.770

FY	2022
营收:	HKD15.27B
毛利润:	HKD6.72B (44.04 %)
EPS:	HKD1.060

FY	2021
营收:	HKD10.29B
毛利润:	HKD4.83B (46.93 %)
EPS:	HKD0.810

Financial Reports:

No articles found.

WuXi Biologics (Cayman)

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.